Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011
Comorbidity and mortality results from a randomized prostate cancer screening trial.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 155 citations in OpenAlex.
- Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.Ontario health technology assessment series · 2015Pooled it
- Screening for prostate cancer.The Cochrane database of systematic reviews · 2013Pooled it
- An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer.Cancer research · 2012Pooled it
- Trial
- Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.Journal of the National Cancer Institute · 2012Trial
- Diagnostic Value of Transabdominal Ultrasound-based Versus Magnetic Resonance Imaging-based Prostate-specific Antigen Density for Clinically Significant Prostate Cancer.European urology open science · 2026Article
- Health-related quality of life in ethnically diverse Black prostate cancer survivors: a convergent parallel mixed-methods approach.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Low-Value Prostate-Specific Antigen Screening in Older Males.JAMA network open · 2023Article
- Age-specific percentile-based prostate-specific antigen cutoff values predict the risk of prostate cancer: A single hospital observation.BioMedicine · 2023Article
- The role of the serum 25-OH vitamin D level on detecting prostate cancer in men with elevated prostate-specific antigen levels.Scientific reports · 2022Article
- A Combined Radiomics and Machine Learning Approach to Distinguish Clinically Significant Prostate Lesions on a Publicly Available MRI Dataset.Journal of imaging · 2021Article
- Impact of 2012 Prostate Cancer Screening Statement.Journal of general internal medicine · 2021Article
- When to Discuss Prostate Cancer Screening With Average-Risk Men.American journal of preventive medicine · 2021Article
- [Intelligent early prostate cancer detection in 2021: more benefit than harm].Der Urologe. Ausg. A · 2021Review
- Narrative review of urinary glycan biomarkers in prostate cancer.Translational andrology and urology · 2021Review
- Test-retest repeatability of a deep learning architecture in detecting and segmenting clinically significant prostate cancer on apparent diffusion coefficient (ADC) maps.European radiology · 2021Article
- Associations among statins, preventive care, and prostate cancer mortality.Prostate cancer and prostatic diseases · 2020Article
- Cancer Screening Among Older Adults: a Geriatrician's Perspective on Breast, Cervical, Colon, Prostate, and Lung Cancer Screening.Current oncology reports · 2020Review
- Are all prostate cancer patients "fit" for salvage radiotherapy?World journal of clinical oncology · 2020Article
- The burden of prostate cancer is associated with human development index: evidence from 87 countries, 1990-2016.The EPMA journal · 2019Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
purposeEstimates of prostate cancer-specific mortality (PCSM) were similar for men randomly assigned to intervention compared with usual care on the Prostate, Lung, Colorectal and Ovarian PC screening study. However, results analyzed by comorbidity strata remain unknown. PATIENTS AND
methodsBetween 1993 and 2001, of 76,693 men who were randomly assigned to usual care or intervention at 10 US centers, 73,378 (96%) completed a questionnaire that inquired about comorbidity and prostate-specific antigen (PSA) testing before random assignment. Fine and Gray's multivariable analysis was performed to assess whether the randomized screening arm was associated with the risk of PCSM in men with no or minimal versus at least one significant comorbidity, adjusting for age and prerandomization PSA testing.
resultsAfter 10 years of follow-up, 9,565 deaths occurred, 164 from PC. A significant decrease in the risk of PCSM (22 v 38 deaths; adjusted hazard ratio [AHR], 0.56; 95% CI, 0.33 to 0.95; P = .03) was observed in men with no or minimal comorbidity randomly assigned to intervention versus usual care, and the additional number needed to treat to prevent one PC death at 10 years was five. Among men with at least one significant comorbidity, those randomly assigned to intervention versus usual care did not have a decreased risk of PCSM (62 v 42 deaths; AHR, 1.43; 95% CI, 0.96 to 2.11; P = .08).
conclusionSelective use of PSA screening for men in good health appears to reduce the risk of PCSM with minimal overtreatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.